Expertise in
13
conditions

Dr. Mark Mckenzie

Internal Medicine
D And D Milne LTD.
2010 Wellness Way Ste 100, 
Las Vegas, NV 
Expertise in
13
conditions
D And D Milne LTD.
2010 Wellness Way Ste 100, 
Las Vegas, NV 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Mckenzie is a primary care provider, practicing in Internal Medicine in Las Vegas, Nevada. Dr. Mckenzie is highly rated in 13 conditions, according to our data. His top areas of expertise are Stroke, Heart Attack, Memory Loss, Gastrostomy, and Endoscopy.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in NV
Hospital Affiliations
Sunrise Hospital And Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Silversummit Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

D and D Milne LTD.
2010 Wellness Way Ste 100, Las Vegas, NV 89106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Intervention Type: Drug
Study Drug: HM15211
Study Phase: Phase 2
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Enrollment Status: Completed
Publish Date: August 11, 2025
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Patients With Celiac Disease (ACeD)
A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Patients With Celiac Disease (ACeD)
Enrollment Status: Completed
Publish Date: August 06, 2024
Intervention Type: Drug
Study Drug: KAN-101
Study Phase: Phase 1
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
Enrollment Status: Completed
Publish Date: January 19, 2024
Intervention Type: Other, Drug
Study Phase: Phase 2
Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C
Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Other
Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening BLUE-C
Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening BLUE-C
Enrollment Status: Completed
Publish Date: September 01, 2023
Intervention Type: Procedure, Diagnostic test
Reference Range Study for the Quantra QStat System
Reference Range Study for the Quantra QStat System
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Diagnostic test
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Drug
Study Drug: Emricasan
Study Phase: Phase 2
View 8 Less Clinical Trials

1 Total Publications

Carotid body tumor as a reversible cause of syncope.
Carotid body tumor as a reversible cause of syncope.
Journal: The Journal of the American Osteopathic Association
Published: November 23, 2011
Similar Doctors
Expertise in
22
conditions
Dr. George Baramidze
Internal Medicine
Expertise in
22
conditions
Dr. George Baramidze
Internal Medicine

Nevada Nephrology Consultants

2820 W Charleston Blvd, Ste 33, 
Las Vegas, NV 
 (3.1 miles away)
702-880-1558
Languages Spoken:
English
See accepted insurances
Accepting New Patients

George Baramidze is an Internal Medicine provider in Las Vegas, Nevada. Dr. Baramidze is highly rated in 22 conditions, according to our data. His top areas of expertise are Acute Kidney Failure, Necrosis, End-Stage Renal Disease (ESRD), and Low Sodium Level. Dr. Baramidze is currently accepting new patients.

Expertise in
10
conditions
Dr. Mark J. Adaimy
Internal Medicine
Expertise in
10
conditions
Dr. Mark J. Adaimy
Internal Medicine

Nevada Nephrology Consultants

2820 W Charleston Blvd, Ste 33, 
Las Vegas, NV 
 (3.1 miles away)
702-880-1558
Languages Spoken:
English, Arabic, Armenian, French
See accepted insurances
Accepting New Patients

Mark Adaimy is an Internal Medicine provider in Las Vegas, Nevada. Dr. Adaimy is highly rated in 10 conditions, according to our data. His top areas of expertise are Acute Kidney Failure, Necrosis, End-Stage Renal Disease (ESRD), and Chronic Kidney Disease. Dr. Adaimy is currently accepting new patients.

Expertise in
15
conditions
Dr. Gary Grossman
Internal Medicine
Expertise in
15
conditions
Dr. Gary Grossman
Internal Medicine

Internal Medicine Spec. Of Southern NV Grossman Panikkar Ghadishah Whi

201 N Buffalo Dr, 
Las Vegas, NV 
 (7.5 miles away)
702-242-2737
Languages Spoken:
English
See accepted insurances

Gary Grossman is a primary care provider, practicing in Internal Medicine in Las Vegas, Nevada. Dr. Grossman is highly rated in 15 conditions, according to our data. His top areas of expertise are Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia (HoFH), Defective Apolipoprotein B-100, and Heterozygous Familial Hypercholesterolemia (HeFH).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mckenzie's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 151 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile